Preclinical cardiovascular diseases and aortic stiffness

Czech version

Authors: Mária Potočárová ¹; Jozef Bulas ¹; Marta Filková Karabová ¹; Ján Murín ¹; Ivan Janiga ²
Authors‘ workplace: I. interná klinika LF UK a UN Bratislava, Slovenská republika, prednostka doc. MUDr. Soňa Kiňová, PhD. ¹; Slovenská technická univerzita Bratislava, Slovenská republika, dekan prof. Ing. Ľubomír Šóoš, PhD. ²
Published in: Vnitř Lék 2014; 60(4): 341-347
Category: 60th Birthday - prof. MUDr. Petr Widimský, DrSc., FESC, FACC

Overview

Aim:
To compare aortic stiffness (represented by aortic pulse wave velocity – PWVao) as a marker of cardiovascular risk with cardiovascular risk estimated by standard scoring systems in treated hypertensive patients.

Patients and methods:
In a group of 41 hypertensive patients without clinical manifestation of cardiovascular disease (18 men/23 women, mean age 59 years) we investigated the presence of risk factors and preclinical cardiovascular diseases. To estimate cardiovascular risk we have used SCORE-HDL model and categorical risk stratification recommended by ESC/ESH. Linear regression was used for evaluation of relation between risk estimation scores and PWVao values.

Results:
We have found out statistically significant relationship between PWVao and cardiovascular risk assessment systems in our group of patients. The correlation between PWVao and ESC/ESH risk stratification (r = 0.414, P < 0.01) was the most relevant, the correlation between PWVao and SCORE-HDL values was also significant (r = 0.315; P < 0.05).

Conclusions:
Increased aortic stiffness as one of the preclinical cardiovascular diseases can be an integrative marker of cardiovascular risk in patients with arterial hypertension.

Key words:
preclinical cardiovascular diseases – cardiovascular risk – aortic pulse wave velocity – PWV – aortic stiffness

Sources

1. 2013 ESH/ESC guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28): 2159–2219.

2. Leoncini G, Ratto E, Viazzi F et al. Increased ambulatory arterial stiffness index is associated with target organ damage in primary hypertension. Hypertension 2006; 48(3): 397–403.

3. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and prevention. Hypertension 2014; 63(4):878–85.

4. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13(1 Pt 2): 3S-10S.

5. Thomas G Assessment of global risk: A foundation for a new, better definition of hypertension. J Clin Hypertens 2006; 8(Suppl 2): 5–14.

6. Kaplan NM. Arterial hypertension. In: Anderson DM et al.Mosby's medical, nursing, and allied health dictionary.6th ed. Mosby: St. Louis (USA) 2002. ISBN 9780323014304.

7. Basile J. Management of Global Risk Across the Continuum of hypertensive Heart disease. J Clin Hypertens (Greenwich) 2006; 8(Suppl 2): 21–30.

8. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement. Am Heart J 1991; 121(4 Pt 1): 1244–1263.

9. Glasser SP, Krasikov T, Devereux RB et al. Sublinical, hemodynamic, and echocardiographic abnormalities of high pulse pressure in hypertensiove and non-hypertensive adults. Am J Cardiol 2012; 2(4): 309–317.

10. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 1993; 88(4 Pt 1): 1444–1455.

11. Volpe M, Battistoni A, Tocci G et al. Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: a role for organ damage markers. J Hypertens 2012; 30(6): 1056–1064.

12. Practice Guidelines For Primary Care Physicians: 2003 ESH/ ESC Hypertension Guidelines. J Hypertens 2003; 21(10): 1779–1786.

13. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force of European Society of Cardiology (ESC) and European Society of Hypertension. Eur Heart J 2007; 28(12):1462–1536.

14. Perk J., De Backer G., Gohlke H. et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of The European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). European Heart J 2012; 33(13): 1635–1701.

15. Goff jr. DC, Lloyd-Jones DM, Bennett G et al. 2013 ACC/AHA Guidelines on the Assessment of Cardiovascular Risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013. Dostupné z DOI: <http://doi:10.1161/01.cir.0000437741.48606.98>.

16. Mitchell GF, Chao-Yu Guo, Benjamin E et al. Cross-Sectional Correlates of Increased Aortic Stiffness in the Community. The Framingham Heart Study. Circulation 2007; 115(20): 2628–2636.

17. Sakuragi S, Abhayaratna WP. Arterial stiffness: Methods of measurement, physiologic determinants and prediction of cardiovascular outcomes. Int J Cardiol 2010; 138(2): 112–118.

18. Palatini P, Casiglia E, Gasowski J et al. Arterial stiffness, central hemodynamics, and cardiovascular risk in hypertension. Vasc Health Risk Manag 2011; 7: 725–739.

19. Simon A, Mijiti W, Gariepy J et al. Current possibilities for detecting high risk of cardiovascular disease. Int J Cardiol 2006; 110(2): 146–152.

20. Miklos I. A new and fast screening method for measuring complex hemodynamical parameters and arterial stiffness non-invasively with a simple arm cuff. Am J Hypertens 2005; 18(5 Pt 2): 15A.

21. Boutouyrie P, Revera M, Parati G. Obtaining arterial stiffness indices from simple arm cuff measurements: the holy grail? J Hypertens 2009; 27(11): 2159–2161.

22. Baulmann J, Schillings U, Rickert S et al. A new oscillometric method for assessment of arterial stiffness: comparison with tonometric and piezoelectronic methods. J Hypertens 2008; 26(3): 523–528.

23. Jatoi NA, Mahmud A, Bennett K et al. Assessment of arterial stiffness in hypertension: comparison of oscillometric (Arteriograph), piezoelectronic (Complior) and tonometric (SphygmoCor) techniques. J Hypertens 2009; 27(11): 2186–2191.

24. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150(9): 604–612. Erratum in: Ann Intern Med 2011; 155(6): 408.

25. Devereux RB, Alonso RD, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy finding. Am J Cardiol 1986; 57(6): 450–458.

26. Kritz H, Schmid P, Karanikas G et al. Detection of Early Atherosclerotic Lesions in the Carotid Artery: Experimental and Preliminary Human Data. Int J Angiol 1997; 6: 24–29.

27. Wilkinson IB, McEniery CM, Cockroft JR. Central blood pressure estimation for the massess moves a step closer. J Hum Hypertens 2010; 24(8): 495–497.

28. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33(17): 1635–1701.

29. Špác J, Souček M, Řiháček I et al. Rychlost aortální pulzové vlny u nemocných s metabolickým syndromem a hypertenzí léčených sartany. Vnitř Lék 2010; 56(8): 880–883.

30. Cao JJ, Arnold AM, Manolio TA et al. Association of Carotid Artery Intima-Media Thickness, Plaques, and C-reactive Protein with Future Cardiovascular Disease and All-Cause Mortality. The Cardiovascular Health Study. Circulation 2007; 116(1): 32–38.

31. Verdecchia P, Carini G, Circo A et al. Left ventricular mass in essential hypertension: the MAVI Study. J Am Coll Cardiol 2001; 38(7): 1829–1835.

32. Olsen MH, Sehestedt T, Lyngbaek S et al. Urine albumin/creatinine ratio, high sensitivity C-reactive protein and N-terminal pro brain natriuretic peptide – three new cardiovascular risk markers – do they improve risk prediction and influence treatment? Current Vasc Pharmacol 2010; 8(1): 134–139.

33. Leoncini G, Sacchi G, Ravera M et al. Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. J Hum Hypertens 2002; 16(6): 399–404.